Publication
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugErdafitinibcivic_curation1.00
- geneFGFR3civic_curation1.00
- variantFGFR3 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (9)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31340094
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Fusion2 | ||||||||
| Erdafitinib | Bladder Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11257In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| 〃 | Transitional Cell Carcinoma | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID7423In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| FGFR3 G370C + FGFR3 R248C + FGFR3 S249C + FGFR3 Y373C1 | ||||||||
| Erdafitinib | Bladder Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11259In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| FGFR3 Fusion2 | ||||||||
| Erdafitinib | Bladder Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11258In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| 〃 | Transitional Cell Carcinoma | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID7424In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| FGFR3 Mutation1 | ||||||||
| Erdafitinib | Transitional Cell Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID7422In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| FGFR3 R248C1 | ||||||||
| Erdafitinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | rejected | EID8281The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alte… (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| FGFR3 Y373C2 | ||||||||
| Erlotinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 5 | rejected | EID8879Use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterati… (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |
| Erdafitinib | Urothelial Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13205In a phase 2 trial of patients with advanced or metastatic urothelial cancer who were positive for FGFR2 fusions or known FGFR3 variants (including Y373C), 40% of patients showed an objective response… (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC | civic |